Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
-
Inter Milan gamble on novice Chivu after end of Inzaghi era
-
What is the high seas treaty?
-
Australia's Smith wary of South Africa pace attack in WTC final
-
England's Tuchel impatient for improvement after dire Andorra display
-
Inter Milan hire Chivu as new coach
-
Le Pen, Orban lambast EU at far-right rally in France
-
South Africa boosted by Broad chat ahead of WTC final against Australia
-
Tottenham closing in on Brentford's Frank in search for new manager
-
Warner Brothers Discovery to split into 2 companies to build streaming
-
US-China trade talks in London hang over markets
-
S.Africa wants return of apartheid-, colonial-era remains
-
TikTok says to increase investment in Britain
-
Australia's Smith fears South Africa pace attack in WTC final
-
US, China begin key trade talks in London
-
Injured Scotland prop Fagerson out of Lions tour
-
England's Tuchel refuses to 'sugarcoat' criticism after dire display against Andorra
-
Russia, Ukraine swap first prisoners in large-scale exchange
-
Monkey business delays Sri Lanka's wildlife survey
-
Defence or environment? UK faces spending choices
-
Stocks diverge awaiting China-US trade talks
-
Chivu leaves Parma ahead of Inter Milan move
-
Hitchcock heroine Novak awarded Venice lifetime achievement award
-
UK to boost 'homegrown talent' in new AI skills drive
-
Beaten Sinner extends lead on Alcaraz at top of ATP rankings
-
Strycova to replace Pala as Czech Billie Jean King Cup team captain
-
Defence or environment? London faces spending choices
-
'Tennis the winner' as Alcaraz and Sinner set for enduring rivalry
-
Don't let deep sea become 'wild west', Guterres tells world leaders
-
Chivu says goodbye to Parma ahead of Inter Milan move
-
Iran says to submit own nuclear proposal to US soon
-
Boisson jumps 296 places in WTA rankings after French Open run
-
China's exports slow as trade war takes toll
-
Tangled humpback whale sparks rescue mission off Australia
-
Malaysia bus crash kills at least 15, mostly students
-
Climate change heightens risk of Indian farmer suicides
-
Farmed production of some fish - and seaweed - is soaring
-
Bust attributed to Donatello splits Slovakia
-
Israel diverts Gaza-bound aid boat carrying Greta Thunberg
-
China exports slow as trade war takes toll
-
'Maybe Happy Ending' tops Broadway's Tony Awards
-
'Flawed' Test Championship reveals world cricket's underlying problems
-
Retired great Hakuho says leaving sumo after bullying scandal
-
Haliburton vows to improve after Thunder defense stifles Pacers
-
Trump travel ban in effect, citizens from 12 nations barred from US
-
McIntosh impresses in 800m free win at Canada trials
-
NATO learns as Ukraine's 'creativity' changes battlefield
-
Thunder rumble to 123-107 win over Pacers to level NBA Finals
-
Israel says Gaza-bound activist boat carrying Greta Thunberg redirected
-
Chinese consumer prices continue to fall as US trade talks loom
-
Thunder power past Pacers to level NBA Finals
NYSE - LSE
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
OXFORD, GB AND GERMANTOWN, MD / ACCESS Newswire / June 9, 2025 / Barinthus Biotherapeutics plc announced that Bill Enright, CEO, will be presenting at the Investor Summit Virtual taking place on June 10.
About Barinthus Biotherapeutics
Barinthus Biotherapeutics (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.
Event: Q2 Investor Summit
Presentation Time: June 10, 11:00 - 11:30 AM ET
Location: WEBCAST LINK
Conference Overview and Structure
The Investor Summit is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various subject matter experts, and see what your peers are doing in this market.
This quarter's event is focused on MicroCap companies who have a near-term catalyst and are undervalued.
Registration for Investors
To request free registration, please go to our website (https://investorsummitgroup.com/), and click the "Registration" button.
Sponsors:
AccessNewswire
PCG Advisory
QuoteMedia
AGP
MZ Group
News Compliments of ACCESSWIRE
For More Information
Please visit: https://investorsummitgroup.com/
Or, contact [email protected]
SOURCE: Investor Summit Group
View the original press release on ACCESS Newswire
P.Stevenson--AMWN
